Recent news in the treatment of lupus nephritis

Minerva Medica

Volumn 103, Issue 4, 2012, Pages 235-251

  Tesar, V ^a   Hruskova, Z ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Belimumab; Cyclosporine; Lupus nephritis; Mychophenolate mofetil; Rituximab

Indexed keywords

AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; KIDNEY DYSFUNCTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; REVIEW;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AZATHIOPRINE; CALCINEURIN; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MAINTENANCE CHEMOTHERAPY; MYCOPHENOLIC ACID;

EID: 84867414797     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413-24. (Pubitemid 29068083)
2. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007;22:2531-9. (Pubitemid 47365517)
3. Weening JJ, D'Agati V, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50. (Pubitemid 38140764)
4. Churg J, Sobin LH. Renal Disease. Classification and Atlas of Glomerular Disease. Tokyo: Igaku-Shoin; 1982.
5. Furness P, Taub N. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study. Am J Surg Pathol 2006;30:1030-5. (Pubitemid 44264954)
6. Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int 2007;71:491-5. (Pubitemid 46398689)
7. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcome. Arthritis Rheum 1995;38:274-83.
8. Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006;69:1846-51. (Pubitemid 43739214)
9. Korbet SM, Schwartz MM, Evans J, Lewis EJ;Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18:244-54. (Pubitemid 46070148)
10. Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy. Arthritis Rheum 2002;46:995-1002.
11. Wernick RM. Reliability of histologic scoring for lupus nephritis:a community-based evaluation. Ann Intern Med 1993;119:805-11. (Pubitemid 24012646)
12. rd, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and histological factors in 166 patients. Nephrol Dial Transplant 1995;10:1620-8.
13. Berden JHM. Lupus nephritis. Kidney Int 1997;52:538-58. (Pubitemid 27359601)
14. Korbet SM, Lewis EJ, Schwartz MM. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000;35:904-14. (Pubitemid 30238204)
15. Alarcon GS, McGwin G Jr, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP;PROFILE Study Group. Baseline characteristics of a multiethnic lupus cohort:PROFILE. Lupus 2002;11:95-101. (Pubitemid 34259439)
16. Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La Cuesta C et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005;14:890-5. (Pubitemid 41736370)
17. Liang, MH, Schur PH, Fortin P, St. Clair EW, Balow JE, Costenbader K et al. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trial. Arthritis Rheum 2006;54:421-32. (Pubitemid 43228616)
18. Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009;18:257-63.
19. Gordon C, Bertsias G, Ioannidis JPA, Boletis J, Bombardiert S, Cervera R et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis 2009;68:470-6.
20. Ioannidis JPA, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-64. (Pubitemid 30227773)
21. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al.:Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28. (Pubitemid 41697285)
22. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-72. (Pubitemid 40559171)
23. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996;50:2047-53. (Pubitemid 26417549)
24. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Arthritis Rheum 2004;50:3934-40.
25. Pablos JL, Gutierrez-Millet V, Gomez-Reino JJ. Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. Scand J Rheumatol 1994;23:142-4. (Pubitemid 24199556)
26. Contreras G, Pardo V, Leclerq B, Lenz O, Tozman E, O'Nan P et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80. (Pubitemid 38269274)
27. Ciruelo E, De La Cruz J, Lopez I, Gómez-Reino JJ et al. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996;12:2028-34. (Pubitemid 27009071)
28. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials:a critical overview. Lupus 1998;7:622-9. (Pubitemid 29008229)
29. Tesar V, Hruskova Z. Treatment of proliferative lupus nephritis:a slowly changing landscape. Nat Rev Nephrol 2011;7:96-109.
30. Pollak VE, Pirani CL, Kark RM. Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis. J Lab Clin Med 1961;57:495-511.
31. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978;299:1151-5. (Pubitemid 9065570)
32. Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J et al. Methylprednislone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1996;125:549-57. (Pubitemid 126450087)
33. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al:Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
34. Carette S, Klippel JH, Decker JL, Austin HA, Plotz PH, Steinberg AD et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. Ann Intern Med 1983;99:1-8. (Pubitemid 13066648)
35. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. N Engl J Med 1984;311:1528-33. (Pubitemid 15223251)
36. Austin HA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH et al. Therapy of lupus nephritis-controlled trial of prednisolone and cytotoxic drugs. N Engl J Med 1986;314:614-9. (Pubitemid 16132725)
37. Balow JE, Austin HA, Muenz LR, Joyce KM, Antonovych TT, Klippel JH et al. Effect of treatment on the evolution of treatment abnormalities in lupus nephritis. N Engl J Med 1984;311:491-6.
38. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis:a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004;43:197-208.
39. Bargman JM. How did cyclophosphamide become the drug of choice for lupus nephritis? Nephrol Dial Transplant 2009;24:381-4.
40. Houssiau FA, D'Cruz DP, Haga HJ, Hughes GR. Short course of weekly low-dose intravenous pulse cyclphosphamide in the treatment of lupus nephritis:a preliminary study. Lupus 1991;1:31-5.
41. Ponticelli C. Treatment of lupus nephritis: the advantages of a flexible approach. Nephrol Dial Transplant 1997;12:2057-9. (Pubitemid 27423240)
42. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-42. (Pubitemid 44215349)
43. Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007;56:924-37. (Pubitemid 46399440)
44. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG et al. Immunosuppressive therapy in lupus nephritis. The Euro-Lupus trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
45. Houssiau FA, Vasconselos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG et al. The 10-year follow-up of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61-4.
46. D'Cruz D, Houssiau FA. The Euro-Lupus Nephritis Trial: the development of sequential treatment protocol. Lupus 2009;18:875-7.
47. Ntali S, Bertsias G, Boumpas T. Cyclophosphamide and lupus nephritis: when, how, for how long? Clinic Rev Allerg Immunol 2011;40:181-91.
48. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004;50:2559-68. (Pubitemid 39062717)
49. Mosca M, Neri R, Giannessi S, Pasquariello A, Puccini R, Bencivelli W et al. Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis. Lupus 2001;10:253-7. (Pubitemid 32332146)
50. Moroni G, Gallelli B, Quaglini S, Banfi G, Rivolta E, Messa P et al. Withdrawal of therapy in patients with proliferative nephritis: long-term follow-up data. Nephrol Dial Transplant 2006;21:1541-8. (Pubitemid 43834637)
51. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:355.e25-355.e33.
52. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156-62.
53. Appel GB, Contreras G, Dooley MA, Ginzier EM, Isenberg D, Jayne D et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-1112.
54. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA;ALMS Group. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis. Arthritis Rheum 2010;62:211-221.
55. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010;49:128-40.
56. Barr RG, Seliger S, Appel GB, Zuniga R, D'Agati V, Salmon J et al. Prognosis in proliferative lupus nephritis: the role of socioeconomic status and race/ethnicity. Nephrol Dial Transplant 2003; 18:2039-46. (Pubitemid 37220309)
57. Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84. (Pubitemid 41710318)
58. Rivera F, Fulladosa X, Poveda R, Frutos MA, García-Frías P, Ara J et al. Mycophenolate as induction therapy in lupus nephritis with renal functional impairment. Am J Nephrol 2012;35:424-33.
59. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 2010;69:2083-9.
60. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95.
61. Stoenoiu MS, Aydin S, Tektonidou M, Ravelingien I, le Guern V, Fiehn C et al. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrol Dial Transplant 2012;27:1924-30.
62. Houssiau FA. Toward better treatment for lupus nephritis. N Engl J Med 2011;365:1929-30.
63. Mercadal L, Montcel ST, Nochy D, Queffeulou G, Piette JC, Isnard-Bagnis C et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002;17:1771-8. (Pubitemid 35174288)
64. Austin HA 3rd, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009;20:901-11.
65. Dostal C, Tesar V, Rychlik I, Zabka J, Vencovský J, BartÛnková J et al. Effect of one year cyclosporine A on the activity and renal involvement of systemic lupus erythematosus:a pilot study. Lupus 1998;7:29-36. (Pubitemid 28052659)
66. Rihova Z, Vankova Z, Maixnerova D, Dostal C, Jancova E, Honsova E et al. Treatment of lupus nephritis with cyclosporine-an outcome analysis. Kidney Blood Press Res 2007;30:124-8. (Pubitemid 46674917)
67. Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 2009;24:15-20.
68. Zavada J, Pesickova SS, Rysava R, Olejarova M, Horák P, Hrncír Z et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 2010;19:1281-9.
69. Moroni G, Doria A, Mosca M, Alberighi OD, Ferraccioli G, Todesco S et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006;1:925-32.
70. Miyasaka N, Kawai S, Hashimoto H:Efficacy and safety of tacrolimus for lupus nephritis:a placebo-controlled double-blind multicenter study. Mod Rheumatol 2009;19:606-15.
71. Rovin BH, McKinley AM, Birmingham DJ. Can we personalize treatment for kidney diseases? Clin J Am Soc Nephrol 2009;4:1670-6.
72. Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int 2008;73:261-8.
73. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82. (Pubitemid 44497778)
74. Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009;24:3717-23.
75. Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus:a longitudinal analysis of 52 Hispanic patients. Lupus 2010;19:213-9.
76. Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009;4:579-87.
77. Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP. Rituximab and mycophenolate mofetil for relapsing proliferate lupus nephritis:a long-term prospective study. Nephrol Dial Transplant 2009;24:2157-60.
78. Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008;35:826-33. (Pubitemid 351747123)
79. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C et al. Clinical and immunological effect of rituximab in patients with lupus nephritis refractory to conventional therapy:a pilot study. Arthritis Res Ther 2006;8:R83.
80. Lu T, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital:The first fifty patients. Arthritis & Rheum 2009;61:482-9.
81. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus:a systematic review of off-label use in 188 cases. Lupus 2009;18:767-76.
82. Calabrese LH, Molloy ES. Therapy: rituximab and PML-risk-informed decisions needed. Nat Rev Rheumatol 2009;528-9.
83. Díaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012;11:357-64.
84. Li EK, Tam LS, Zhu TY, Li M, Kwok CL, Li TK et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford), 2009;48:892-8.
85. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arhritis Rheum 2012;64:1215-26.
86. Favas C, Isenberg DA. B-cell depletion therapy in SLE-what are the current prospects of its acceptance? Nat Rev Rheumatol 2009;5:711-6.
87. Isenberg DA. Rituximab-it was the best of times, it was the worst of times. Autoimmun Rev 2012 [Epub ahead of print].
88. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus:a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
89. Ponticelli C, Glassock RJ, Moroni G. Induction and maintenance treatment in proliferative lupus nephritis. J Nephrol 2010;23:9-16.
90. Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Panzeri P et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001;37:490-8.
91. Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L et al. Urinary TWEAK as a biomarker of lupus nephritis:a multicenter cohort study. Arthritis Res Ther 2009;11:R143.
92. Zhang X, Jin M, Wu H, Nadasdy T, Nadasdy G, Harris N et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int 2008;74:799-807.
93. Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004;43:28-36. (Pubitemid 38049432)